TITLE

New HIV treatment to be distributed through lottery

AUTHOR(S)
Snyder, Karyn
PUB. DATE
July 1995
SOURCE
Drug Topics;7/10/95, Vol. 139 Issue 13, p40
SOURCE TYPE
Trade Publication
DOC. TYPE
Article
ABSTRACT
Reports that Hoffman-La Roche has initiated a treatment program that will supply Invirase (saquinavir) to AIDS patients who may benefit from the drug but who are not eligible for ongoing clinical trials. Direct distribution of saquinavir to physicians; Saquinavir as proteinase inhibitor that blocks a proteinase enzyme critical to the replication of HIV.
ACCESSION #
9508212737

 

Related Articles

  • Combination study of Invirase and Norvir starting.  // AIDS Patient Care & STDs;Jun96, Vol. 10 Issue 3, p187 

    Announces the clinical trial to be conducted by Hoffman-La Roche Inc. with Abbott Laboratories on the protease inhibitors Invirase in combination with Norvir and their effectiveness in the treatment of HIV/AIDS. Distinct mutation profile of Invirase.

  • Pharmacy care Kit available from Roche.  // Drug Topics;10/10/94, Vol. 138 Issue 19, p8 

    Reports on the availability of a pharmacy counseling service from Roche Laboratories for patients on Roferon-A therapy.

  • Toradol labeling changed.  // Drug Topics;3/6/95, Vol. 139 Issue 5, p8 

    Reports on Roche Laboratories decision to change the labeling on its Toradol prescription pain reliever due to reports on side effects from improper use. Usage of the drug for pain management in postsurgical patients.

  • Program prevents pregnancies during tx.  // Dermatology Times;Sep95, Vol. 16 Issue 9, p3 

    Reports on the pregnancy prevention program conducted by Hoffman-La Roche Inc. during isotretinoin treatment for its patients.

  • La Roche lottery.  // Northern New Jersey Business;6/28/95, Vol. 3 Issue 13, p3 

    Reports on the US Food and Drug Administration's approval of the drug called Invirase, manufactured by Hoffman-La Roche.

  • Roche cuts controversial PCR fees, testing limits. Anderson, C. // Nature;1/30/1992, Vol. 355 Issue 6359, p379 

    Reports that Swiss-owned pharmaceutical company Hoffmann-La Roche, under pressure from researchers and diagnostic companies, agreed to lower its prices on its polymerase chain reaction (PCR) technology and lift restrictions on its use. The move should free the technology for widespread use in...

  • Licences sought from PCR users in Britain. Dickson, David // Nature;1/28/1993, Vol. 361 Issue 6410, p291 

    Reports that genetic-screening devices throughout Britain could have their costs increase significantly as a result of claims for royalties on one of the basic laboratory techniques used in diagnostic testing, polymerase chain reaction (PCR). Recent granting of two patents on the PCR process by...

  • Roche fails to get European patent on Taq polymerase. Dickson, David // Nature;7/11/1996, Vol. 382 Issue 6587, p100 

    Reports that the European Patent Office has rejected a claim from pharmaceutical company Hoffmann-La Roche for a patent on the naturally occurring version of thermostable enzyme Taq polymerase. Use of Taq polymerase to amplify small amounts of DNA.

  • Rocephin hotline.  // Drug Topics;11/8/93, Vol. 137 Issue 21, p88 

    Announces the toll-free phone number installed by Roche Laboratories. Answering of reimbursement questions on Rocephin; Operating time.

  • Progan studies against CMV disease on hold.  // AIDS Patient Care & STDs;Oct97, Vol. 11 Issue 5, p375 

    Focuses on the Hoffman La Roche company and how he plans to stop the development of two pro-drug studies. Information on the drug and its achievements; Details on whether it could increase or eliminate the need for intravenous treatment.

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics